The Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size in the 7MM is going to be ~USD 1,843 million in 2025, and expected to grow with a CAGR of 7.6% during the forecast perio

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the CIDP Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report

* In 2023, the US accounted for the highest diagnosed prevalent cases of CIDP with approximately 30,230 cases, which are expected to increase by 2036.
* Among EU4 and the UK, the UK had the highest diagnosed prevalent cases of CIDP, with nearly 3,250 cases in 2023, followed by Germany with around 3,174 cases. In contrast, Spain has the lowest number, with nearly 1,691 cases.
* In 2023, Japan accounted for approximately 2,045 diagnosed prevalent cases of CIDP which are expected to increase by 2036.
* In 2023, among the subtype-specific cases of CIDP, the US accounted for approximately 15,417 cases for typical CIDP and 14,813 cases for atypical CIDP.
* In 2023, Germany had approximately 2,380 males and 793 females diagnosed with CIDP.
* In 2023, the diagnosed prevalent cases of CIDP across the age groups 0-19 years, 20-39 years, 40-59 years, 60-79 years and 80 years and older were approximately 41, 82, 798, 900 and 225, respectively, in Japan.
* The leading Chronic Inflammatory Demyelinating Polyneuropathy Companies include CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals , and others.
* Promising Chronic Inflammatory Demyelinating Polyneuropathy Therapies include Riliprubart, Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Efgartigimod PH20 SC, SAR445088 (IV) , and others.

Stay ahead in the CIDP Therapeutics Market with DelveInsight's Strategic Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Inflammatory Demyelinating Polyneuropathy Overview

Chronic inflammatory demyelinating polyneuropathy is a rare neurological disorder characterized by inflammation and damage to the protective covering of nerves, known as the myelin sheath. This damage disrupts the communication between nerves and muscles, leading to progressive weakness and impaired sensory function. CIDP is clinically classified into typical and atypical forms. The typical form, the most common, involves symmetrical polyneuropathy, where both proximal and distal muscles are equally affected, leading to widespread weakness and sensory deficits. Symptoms usually progress gradually, but severity varies among patients, impacting walking, fine motor skills, and daily activities.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation in the 7MM

* Total Chronic Inflammatory Demyelinating Polyneuropathy Prevalent Cases
* Chronic Inflammatory Demyelinating Polyneuropathy Gender-specific Cases
* Chronic Inflammatory Demyelinating Polyneuropathy Clinical Subtype based Diagnosed Cases
* Chronic Inflammatory Demyelinating Polyneuropathy Age-Specific Prevalent Population Cases

Download the report to understand which factors are driving CIDP epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Prevalence [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Inflammatory Demyelinating Polyneuropathy Marketed Drugs

* HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda

HYQVIA is an immunostimulant combining human immunoglobulin (IG 10%) with recombinant human hyaluronidase, enabling SC for easier administration. This treatment offers a convenient alternative to IVIg by allowing larger-volume, less frequent SC due to enhanced absorption. HYQVIA modulates the immune system to reduce autoimmune damage to the nerves in CIDP. In January 2024, the US FDA approved HYQVIA for the maintenance treatment of CIDP in adults. The European Commission also approved it for the same purpose, and the UK's MHRA granted approval in March 2024. Takeda filed for approval in Japan in August 2024.

* VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx

VYVGART HYTRULO is a coformulation of efgartigimod alfa and recombinant human hyaluronidase, designed to enhance SC absorption. It works by reducing autoantibodies implicated in CIDP through inhibition of the FcRn receptor. Approved by the US FDA in June 2024, it received orphan drug designation for CIDP in 2021. This therapy offers a convenient option for maintaining remission via SC administration.

* GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda

GAMMAGARD LIQUID/KIOVIG is a ready-to-use IV formulation of IVIg derived from human plasma, offering a broad spectrum of antibodies. It works by modulating the immune system, reducing inflammation, and preventing further nerve damage in CIDP. Clinical studies have shown its effectiveness in improving muscle strength and functional ability, helping manage symptoms and maintain long-term stability. It was approved by the US FDA in January 2024 for adults with CIDP. In May 2019, KIOVIG was also approved in the EU for treating CIDP in adults, children, and adolescents (0-18 years).

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs

* Riliprubart (SAR445088): Sanofi

Riliprubart (SAR445088) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. By blocking C1s, riliprubart has the potential to inhibit key inflammatory mechanisms that drive demyelination and axonal damage in CIDP. Riliprubart has convenient subcutaneous route of administration. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of CIDP.

* Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences

Batoclimab is a human monoclonal antibody directed against the Neonatal Crystallizable Fragment Receptor (FcRn), with potential immunomodulating activity. Upon administration, batoclimab targets and binds to FcRn at the Immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, batoclimab blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes. Immunovant reported topline results in March 2025 from its Phase IIb study of batoclimab in CIDP, showing meaningful improvements in disability scores during the initial 12-week period. Patients with deeper reductions in IgG levels demonstrated higher responder rates.

Get In-Depth Knowledge on CIDP Market Trends and Forecasts with DelveInsight @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook

Chronic inflammatory demyelinating polyneuropathy, though classified as a rare disease, has gained increasing recognition in recent years. This is largely due to improvements in diagnostic techniques, greater awareness among healthcare professionals, and a deeper understanding of the condition. Management of CIDP typically involves a combination of pharmacological therapies and supportive interventions, with the primary objectives to suppress inflammation, modulate immune responses, and improve motor and sensory function.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Landscape

The treatment landscape for CIDP has advanced with a multi-faceted approach, combining medications, and supportive care. Corticosteroids, such as prednisone and dexamethasone, are often the initial treatment. While they are effective in inducing remission, they carry a high risk of significant long-term side effects, including osteoporosis, weight gain, and increased susceptibility to infections. These adverse effects often necessitate combination therapies with steroid-sparing agents, which may not be universally effective. Plasma exchange has shown short-term efficacy in removing harmful autoantibodies and improving symptoms. However, it is an invasive procedure that requires highly specialized centers and trained personnel, limiting its accessibility, IVIg has become the gold standard due to its demonstrated efficacy in long-term disease control and symptom improvement. Despite this, IVIg is costly, time-consuming, and heavily reliant on donor plasma, raising concerns about its long-term availability.

Unlock Strategic Insights with DelveInsight's Comprehensive CIDP Market Report @ CIDP Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market

* Coverage- 7MM
* Study Period- 2022-2036
* Forecast Period- 2026-2036
* Chronic Inflammatory Demyelinating Polyneuropathy Companies- CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others.
* Chronic Inflammatory Demyelinating Polyneuropathy Therapies- Riliprubart, Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Efgartigimod PH20 SC, SAR445088 (IV) , and others.
* Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers
* Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction

3. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance

4. Chronic Inflammatory Demyelinating Polyneuropathy Methodology

5. Chronic Inflammatory Demyelinating Polyneuropathy Executive Summary

6. Chronic Inflammatory Demyelinating Polyneuropathy Disease Background and Overview

7. Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population

8. Chronic Inflammatory Demyelinating Polyneuropathy Treatment

9. Diagnostic and Treatment Guidelines for Chronic Inflammatory Demyelinating Polyneuropathy

10. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs

11. Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey

12. Chronic Inflammatory Demyelinating Polyneuropathy Approved Therapies

13. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies

14. Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis

15. Chronic Inflammatory Demyelinating Polyneuropathy KOL Views

16. Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers

17. Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers

18. Chronic Inflammatory Demyelinating Polyneuropathy SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=the-chronic-inflammatory-demyelinating-polyneuropathy-therapeutics-market-size-in-the-7mm-is-going-to-be-usd-1843-million-in-2025-and-expected-to-grow-with-a-cagr-of-76-during-the-forecast-perio]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.